FGFR2 as an actionable target in iCCA has been tested in a number of clinical trials.20–25 FGFR2 genetic aberrations (assessed by NGS or FISH) were found to be more frequent in young and female patients with earlier tumour stage. Here, FGFR2 is linked to infantile convulsions and choreoathetosis.